The endocannabinoid system (ECS), consisting of the cannabinoid receptors CB1 and CB2, their major endogenous ligands 2-arachidonylglycerol (2-AG) and arachidonoylethanolamide (AEA or anandamide), and their synthesizing and degrading enzymes, plays a crucial role in the intrinsic response to neuroinflammation, brain injury, and neurodegenerative diseases [1,2,3]. This evidence concerns the gene CNR2 and neurodegenerative disease.